Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

NCT03546842 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Papillomavirus Infections
Uterine Cervical Neoplasms
Vulvar Neoplasms
Vaginal Neoplasms
Adenocarcinoma in Situ
Condylomata Acuminata

Interventions

BIOLOGICAL: 9vHPV vaccine

Sponsor

Merck Sharp & Dohme LLC